pSivida Corp (PSDV) Announces Initiation of Phase III Clinical Trial in Posterior Uveitis
7/1/2013 8:28:41 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that it has initiated the first of two planned pivotal Phase III trials of its micro-insert for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye, a major cause of vision loss in the U.S.
Help employers find you! Check out all the jobs and post your resume.
comments powered by